EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Plus Therapeutics, Inc. for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on February 24, 2022, (the “Report”), Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:
|
1. |
The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934. |
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Plus Therapeutics, Inc. |
|
|
|
By: |
|
/s/ Marc H. Hedrick, MD |
|
Dated: February 24, 2022 |
|
|
|
Marc H. Hedrick, MD |
|
|
|
|
|
President & Chief Executive Officer |
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Andrew Sims |
|
Dated: February 24, 2022 |
|
|
|
Andrew Sims |
|
|
|
|
|
Chief Financial Officer |